Cargando…
A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma
Metaplastic breast carcinoma (MBC) is a rare malignant breast tumor, and no effective chemotherapy unique to metaplastic carcinoma exists. As MBC is typically “triple negative”, endocrine therapy and molecular therapy targeted to Her2 might not be favorable, resulting in a poor prognosis. Anlotinib...
Autores principales: | Zou, Jieya, Yang, Xiaojuan, Duan, Jiajun, Wang, Ji, Yang, Zhuangqing, Luo, Dan, Liu, Lihua, Chen, Junyao, Nie, Jianyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408045/ https://www.ncbi.nlm.nih.gov/pubmed/34475766 http://dx.doi.org/10.2147/OTT.S318645 |
Ejemplares similares
-
The application of methylene blue coloration technique in axillary lymph node dissection of breast cancer
por: Zou, Jieya, et al.
Publicado: (2019) -
Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
por: Fu, Yang, et al.
Publicado: (2022) -
Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022) -
Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast
por: Xiao, Meng, et al.
Publicado: (2017) -
Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma
por: Lien, Huang-Chun, et al.
Publicado: (2023)